Novelion Therapeutics Inc. announced that each of Mark Corrigan, Donald Stern, John Thomas and John Orloff resigned from his respective position as a member of the company and any committee thereof, effective at the Closing. Also, upon and in connection with the Closing, Roger Louis will no longer be serving as Novelion’s Global Chief Compliance Officer and Interim Head of Research and Development.